Hoth Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Knie Robb, was filed 19 Aug 2024.
Hoth Therapeutics, Inc.: what insiders have been doing
Hoth Therapeutics, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Hoth Therapeutics, Inc. The previous disclosure was published on 28 August 2025.
The full history, which starts in 2019, counts 3 purchases against 2 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -12.5 m USD.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 310,744 shares@ US$1.2193.3% of flowCommon StockSEC:0001213900-25-081945:1
- 800,000 shares0Common StockSEC:0001213900-25-081945:0
- 25,000 shares@ US$0.6765.9% of flowCommon StockSEC:0001213900-24-070415:0Canonical exit: 14 Nov 2024 (T+90)
- 5,075 sharesCommon StockSEC:0001213900-22-079538:0
- 10,000 shares@ US$0.3916.8% of flowCommon StockSEC:0001213900-22-057162:0Canonical exit: 18 Dec 2022 (T+90)
- 10,000 shares@ US$0.4017.3% of flowCommon StockSEC:0001213900-22-056813:0Canonical exit: 15 Dec 2022 (T+90)
- 00Common Stock, par value $0.0001SEC:0001213900-21-009744:0
- 400,000 shares@ US$1.25100.0% of flowCommon Stock, par value $0.0001SEC:0001213900-20-013694:0
- 3,333 sharesCommon StockSEC:0001213900-20-009453:0
- 3,333 sharesCommon StockSEC:0001213900-20-009344:0
- 750,000 sharesCommon StockSEC:0001213900-19-003530:0
- 15,000 sharesCommon StockSEC:0001213900-19-003528:0
12 of 12 declarations
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for skin diseases. It aims to provide therapeutic solutions to enhance patients' quality of life.
